Clinical AI, drug discovery, devices, and regulatory approvals.
November's elections may reshape federal health policy on drug pricing, Medicaid, and research funding, with Democratic gains potentially forcing changes despite needing presidential approval.
A meta-analysis of over 265,000 people links cannabis use to elevated rates of both committing and experiencing violence, though causality remains unclear.
State data shows hundreds of thousands of lawfully present immigrants will lose Medicaid coverage starting Oct. 1, exceeding earlier federal estimates.
Two studies discussed on the TTHealthWatch podcast highlight the value of care coordination in primary care and the limited overall benefit of statins in healthy older adults.
The non-covalent BTK inhibitor pirtobrutinib is now approved as initial therapy for adults with CLL/SLL without 17p deletion, based on a trial showing an 80% reduction in progression or death risk versus chemoimmunotherapy.
New research ties a gut-produced molecule to Alzheimer's biomarkers and cognitive decline, suggesting a possible future treatment target.
A new Australian study shows that even UV exposure too mild to cause sunburn can still trigger DNA damage that accumulates over time.
A large England study finds 59% of people with high blood pressure are unaware and half of treated patients remain uncontrolled, prompting calls for proactive screening.
Researchers identified a metabolic vulnerability in high-risk myelodysplastic syndrome stem cells that could be exploited with targeted therapies.
A phase 2 trial found vitamin C did not slow abnormal cell growth but was linked to fewer complications and deaths in people with precancerous blood disorders.
New insights into chronic spontaneous urticaria challenge the IgE-centric model and point to targeted therapies.
The FDA faces a busy fourth quarter with decisions on a novel cancer immunotherapy and Roche's breast cancer drug, while its top leadership remains unsettled.
A small phase II trial found durable clinical benefits and immunotherapy-free remission in generalized myasthenia gravis patients treated with the CAR-T cell therapy miv-cel.
A biotech roundup covers new PhRMA leadership, a third FDA attempt for Ebvallo, and fresh approvals for Mirum and AbbVie.
Cigna announced a $3 billion productivity initiative centered on AI-driven automation, supplier management, and employee efficiency.
New research shows the Alzheimer's risk gene APOE4 actively damages brain blood vessels and impairs protein clearance, but these effects were partially reversed in the lab, pointing to new therapeutic targets.
An analysis of HHS Secretary Robert F. Kennedy Jr.'s public statements finds consistent use of fear-based falsehoods and cherry-picked data that undermine public health.
New pooled data from the phase I/II ACHIEVE trial suggest the investigational drug z-basivarsen produces sustained functional and strength improvements in myotonic dystrophy type 1.